Do I need genetic testing while taking gefitinib?

Yes, genetic testing is often required while taking gefitinib, especially for patients with non-small cell lung cancer (NSCLC). This is because gefitinib is mainly used to treat patients with epidermal growth factor receptor (EGFR) mutations in NSCLC. EGFRmutation is a common molecular abnormality that can be found in NSCLC patients. Gefitinib has shown significant efficacy in EGFR mutation-positive patients, able to prolong survival, reduce symptoms, and improve quality of life. Therefore, determining whether a patient carries an EGFR mutation is key to making treatment decisions. Typically, doctors recommend that NSCLC patients undergo genetic testing to determine the mutation status of their EGFR gene. If a patient is found to carry an EGFR mutation, gefitinib may be considered a suitable treatment option. If there is no EGFR mutation, doctors may consider other treatment options, such as chemotherapy, immunotherapy, or other targeted drugs.